ArticlePLoS pathogens2022
Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study.
Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Serial cycle threshold to assess the infectious potential of SARS-CoV-2: A systematic review.Epidemiology and infection · 2026Pooled it
- Duration of SARS-CoV-2 shedding: A systematic review.Journal of global health · 2024Pooled it
- Quantifying Heterogeneous Impacts of Geolocated mHealth Tracing on Spatiotemporal Transmission of Emerging Infections.GeoHealth · 2026Article
- Quantitative analysis of massive SARS-CoV-2 testing in the community in France in 2021-2022 reveals the associations of variant, vaccination, and age with viral dynamics in symptomatic individuals.PLoS computational biology · 2026Article
- Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza.Nature communications · 2026Article
- Epstein Barr viral shedding dynamics in saliva during acute SARS-CoV-2 infection.medRxiv : the preprint server for health sciences · 2026Article
- Exploratory pharmacokinetic-pharmacodynamic characterization and safety of standardizedFrontiers in pharmacology · 2026Article
- Accuracy of saliva tests for SARS-CoV-2 diagnosis during the pandemic in Rio de Janeiro, Brazil.Scientific reports · 2025Article
- Cycle threshold values and SARS-CoV-2 variant associations with breakthrough infections: a retrospective study in Accra, Ghana.BMC infectious diseases · 2025Article
- Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Circulating neutralizing antibodies and SARS-CoV-2 variant replication following postvaccination infections.JCI insight · 2025Article
- Prevalence, Patterns, and Predictors of SARS-CoV-2 RNA and Culturable Virus in Tears of a Case-Ascertained Household Cohort.American journal of ophthalmology · 2024Article
- Early biological markers of post-acute sequelae of SARS-CoV-2 infection.Nature communications · 2024Article
- Review
- SARS-CoV-2 Polymerase Chain Reaction Cycle Threshold Trends in Patients Who Are Immunocompromised and Implications for Isolation Precautions.Open forum infectious diseases · 2024Article
- Dynamic SARS-CoV-2 surveillance model combining seroprevalence and wastewater concentrations for post-vaccine disease burden estimates.Communications medicine · 2024Article
- Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.Pathogens & immunity · 2024Article
- Does the COVID-19 Vaccination Reduce the Risk to Transmit SARS-CoV-2 to Others?Advances in experimental medicine and biology · 2024Review
- Computational Modeling Insights into Extreme Heterogeneity in COVID-19 Nasal Swab Data.Viruses · 2023Article
- Wastewater and seroprevalence for pandemic preparedness: variant analysis, vaccination effect, and hospitalization forecasting for SARS-CoV-2, in Jefferson County, Kentucky.medRxiv : the preprint server for health sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 2 institutions in 1 country.
Funding
Abstract
The impact of vaccination on SARS-CoV-2 infectiousness is not well understood. We compared longitudinal viral shedding dynamics in unvaccinated and fully vaccinated adults. SARS-CoV-2-infected adults were enrolled within 5 days of symptom onset and nasal specimens were self-collected daily for two weeks and intermittently for an additional two weeks. SARS-CoV-2 RNA load and infectious virus were analyzed relative to symptom onset stratified by vaccination status. We tested 1080 nasal specimens from 52 unvaccinated adults enrolled in the pre-Delta period and 32 fully vaccinated adults with predominantly Delta infections. While we observed no differences by vaccination status in maximum RNA levels, maximum infectious titers and the median duration of viral RNA shedding, the rate of decay from the maximum RNA load was faster among vaccinated; maximum infectious titers and maximum RNA levels were highly correlated. Furthermore, amongst participants with infectious virus, median duration of infectious virus detection was reduced from 7.5 days (IQR: 6.0-9.0) in unvaccinated participants to 6 days (IQR: 5.0-8.0) in those vaccinated (P = 0.02). Accordingly, the odds of shedding infectious virus from days 6 to 12 post-onset were lower among vaccinated participants than unvaccinated participants (OR 0.42 95% CI 0.19-0.89). These results indicate that vaccination had reduced the probability of shedding infectious virus after 5 days from symptom onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.